AAIC 2021 | The importance of new methods for monitoring tau pathology

Alexis Moscoso, PhD, University of Gothenburg, Gothenburg, Sweden, explains the need for new biomarkers for use in Alzheimer’s disease clinical trials. There has been a growing interest in agents that target tau pathology for the treatment of Alzheimer’s in recent years, given the repeated failure of many amyloid targeting agents. Therefore, developing biomarkers that can shed light on the presence and progression of tau pathology is critical. Dr Moscoso outlines the currently available biomarkers, highlighting the benefits that fluid biomarkers have over the well-established amyloid PET imaging. Most recently, plasma biomarkers have shown great promise and may represent an important development to enable the investigation of new agents. This interview took place during the Alzheimer’s Association International Conference 2021.